| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Natural phytoestrogen
Dihydroresveratrol is a hormone receptor modulator and a potent phytoestrogen. It promotes prostate and breast cancer cell growth at picomolar and nanomolar concentrations. It modulates voltage-gated K+ channels. It suppresses the NF-κB signaling pathway. |
|---|---|
| ln Vitro |
Prostate cancer cells PC-3 grow substantially more when treated with 0.1 nM-0.1 μM dihydroresveratrol [1].
In vitro, dihydroresveratrol has antiproliferative activity against human prostate cancer PC3 cells. It promotes prostate and breast cancer cell growth at picomolar and nanomolar concentrations. It scavenges reactive oxygen species and modulates pathways like NF-κB and PI3K/Akt. |
| ln Vivo |
In vivo, dihydroresveratrol ameliorates acute pancreatitis-associated lung injury via inhibitory modulation of the pro-inflammatory response, which is associated with suppression of the NF-κB signaling pathway. It has been studied for potential benefits in cardiovascular health, neuroprotection, and cancer prevention.
|
| Enzyme Assay |
In vitro receptor binding assays for dihydroresveratrol typically use membrane preparations from cells expressing estrogen receptors. Radiolabeled estradiol is displaced by increasing concentrations of the compound to determine binding affinity. Functional assays measure the compound's ability to modulate estrogen receptor-mediated transcription.
|
| Cell Assay |
Background: Recent studies showed that moderate consumption of red or white wines increased the chances of breast cancer, while similar consumption of red wines, rich in trans-resveratrol (trans-R), decreased the rate of prostate cancer. This prompted us to explore the role of various forms of R in cancer proliferation.
Results: Trans-R was found to be the most potent antiproliferative agent. Cis-R demonstrated somewhat less potency compared to trans-R. Unlike cis-R and trans-R, dihydro-R exhibits moderate proliferative effect on androgen-independent prostate cancer cell lines PC-3 and DU-145 at picomolar concentrations. At higher concentrations, dihydro-R caused proliferation inhibition, similar to cis-R and trans-R. The proliferative effect of dihydro-R at low concentrations can be reversed by trans-R which acts as a partial antagonist in the presence of dihydro-R. Mixtures of dihydro-R and trans-R demonstrated complex non-monotonic cross-modulation activity patterns.
Conclusions: Dihydro-R exhibits proliferative effects in androgen-independent prostate cancer cells at picomolar and nanomolar concentrations. While the exact mechanism of these effects requires further evaluation, our preliminary results point to hormone receptor modulation activity. We also observed strong cross modulation between trans-R and dihydro-R at sub-picomolar concentrations. The role of dihydro-R in cancer proliferation related to moderate consumption of red wine remains an open question because dihydro-R has a very complex activity pattern in the presence of trans-R.[1]
Cell-based assays for dihydroresveratrol involve treating prostate and breast cancer cell lines with the compound and measuring cell proliferation, apoptosis, and signaling pathway activation. Cell viability is assessed using MTT assays. NF-κB and PI3K/Akt pathway activation is assessed by Western blot. |
| Animal Protocol |
In vivo animal studies for dihydroresveratrol typically involve administration to animal models of pancreatitis, cardiovascular disease, or cancer. Efficacy is assessed by measuring inflammatory markers, tissue injury, and tumor growth. The compound's ability to modulate oxidative stress and inflammation is evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of dihydroresveratrol are characterized by its role as a resveratrol metabolite. It may have better bioavailability than its parent compound. Glucuronide conjugates are found in human urine after oral intake of resveratrol-containing dietary supplements.
|
| Toxicity/Toxicokinetics |
Dihydroresveratrol is generally considered to have low toxicity as a natural polyphenol. It is a metabolite of resveratrol produced by gut microbiota. High doses may cause mild gastrointestinal disturbances. It has a favorable safety profile.
|
| References | |
| Additional Infomation |
Dihydroresveratrol is a stilbene compound with the structure 1,1'-ethane-1,2-dimethyldiphenyl, with hydroxyl groups attached at the 1, 3, and 4' positions. It is both an exogenous metabolite and a plant metabolite. It has been reported that dihydroresveratrol is found in hydrangeas (Hydrangea serrata), calla lilies (Maackia amurensis), and other organisms with relevant data.
Dihydroresveratrol is a metabolite of resveratrol and a potent phytoestrogen. It is being investigated for its potential therapeutic applications in cardiovascular health, neuroprotection, and cancer prevention. It is not currently approved for therapeutic use. |
| Molecular Formula |
C14H14O3
|
|---|---|
| Molecular Weight |
230.2592
|
| Exact Mass |
230.094
|
| CAS # |
58436-28-5
|
| PubChem CID |
185914
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
430.3±14.0 °C at 760 mmHg
|
| Flash Point |
210.9±14.7 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.662
|
| LogP |
2.51
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
17
|
| Complexity |
214
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
HITJFUSPLYBJPE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H14O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h3-9,15-17H,1-2H2
|
| Chemical Name |
5-[2-(4-Hydroxyphenyl)ethyl]benzene-1,3-diol
|
| Synonyms |
Dihydroresveratrol; Di-hydroresveratrol; Dihydroresveratrol; 58436-28-5; 5-[2-(4-hydroxyphenyl)ethyl]benzene-1,3-diol; 3,4',5-Trihydroxybibenzyl; 5-(4-hydroxyphenethyl)benzene-1,3-diol; Dihydro-Resveratrol; CHEBI:4582; UNII-CBY43AY0TT; Di hydroresveratrol; DHRSV
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~434.29 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.86 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.86 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.86 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3429 mL | 21.7146 mL | 43.4292 mL | |
| 5 mM | 0.8686 mL | 4.3429 mL | 8.6858 mL | |
| 10 mM | 0.4343 mL | 2.1715 mL | 4.3429 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA